News

Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine

SAN DIEGO–(BUSINESS WIRE) — La Jolla Pharmaceutical Company (LJPC) (La Jolla) today announced that results of the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC-501 (angiotensin II) have been published online by The New England Journal of Medicine (NEJM). The article, entitled “Angiotensin II for the Treatment of Vasodilatory Shock,” also will be published in the May 25, 2017 print issue of NEJM.

2017-06-20T13:22:03+00:00